This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1902)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(121)
- EPAR - All authorised presentations(1975)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2699)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(139)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(41)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(3)
- EPAR - Overview(1971)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1875)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1971)
- EPAR - Public assessment report(1547)
- EPAR - Risk-management-plan summary(1133)
- EPAR - Scientific conclusion(1353)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(246)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(163)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1247)
- Newsletter(298)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4049)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2753)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5475)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5304)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2764)
- Regulatory and procedural guideline(722)
- Report(1616)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1224)
- Summary of opinion - Initial authorisation(1672)
- Supply shortage(58)
- Template or form(478)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)Maximum Residue Limits - Summary of opinion(14)
- Advanced therapies(0)
- Antimicrobial resistance(0)
- Biologicals(0)
- Biosimilars(0)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(0)
- Corporate(0)
- COVID-19(0)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(0)
- Governance(0)
- Innovation(0)
- Maximum residue limit(13)
- Medication error(0)
- Medicines(8)
- Medicines for use outside the EU(0)
- Medicine shortages(0)
- Mpox(0)
- Paediatrics(0)
- Parallel distribution(0)
- Pharmacovigilance(0)
- Procurement(0)
- Product information(0)
- Quality of medicines(0)
- Rare diseases(1)
- Referrals(0)
- Regulatory and procedural guidance(0)
- Research and development(0)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(0)
- Veterinary limited markets(0)
Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate
English (EN) (111.06 KB - PDF)
Ketoprofen (poultry) - Summary opinion of the CVMP on the extension of maximum residue limits
English (EN) (121.37 KB - PDF)
Rafoxanide (Bovine and ovine milk) - Summary opinion of the CVMP on the establishment of maximum residue limits
English (EN) (130.14 KB - PDF)
Praziquantel (all ruminants except bovine, Equidae, fin fish) - Summary opinion of the CVMP on the establishment of maximum residue limits
English (EN) (128.86 KB - PDF)
Toltrazuril (poultry eggs) - Summary opinion of the CVMP on the extension of maximum residue limits
English (EN) (132.77 KB - PDF)
Bambermycin (poultry) - Summary opinion of the CVMP on the establishment of maximum residue limits
English (EN) (135.48 KB - PDF)
Bupivacaine - Summary opinion of the CVMP on the establishment of maximum residue limits
English (EN) (121.83 KB - PDF)
Dicyclanil - Summary opinion of the CVMP on the establishment of maximum residue limits
On 10 October 2019, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion recommending that the current entry for dicyclanil in ovine.
English (EN) (115.71 KB - PDF)
Ovotransferrin - Summary opinion of the CVMP on the establishment of maximum residue limits
English (EN) (70.42 KB - PDF)
Diflubenzuron - Summary opinion of the CVMP on the establishment of maximum residue limits AA
On 15 March 2018, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion recommending the amendment of the entry for diflubenzuron.
English (EN) (67.98 KB - PDF)